Twist Bioscience expands clonal genes portfolio with Complex Genes

Twist Bioscience (TWST) expanded its clonal genes portfolio with the early access launch of Complex Genes. Sequences with complex elements have historically been difficult to produce at commercial scale. Leveraging its proprietary silicon-based DNA synthesis platform and improved downstream processes in manufacturing, automation, and sequencing, Twist can now reliably synthesize and deliver these previously out-of-reach complex sequences at scale. Complex sequence elements such as short tandem, inverted and long repeats, as well as high or low GC content and more, can be essential components of customers’ sequences in the development of nucleic acid therapeutics such as cell and gene therapies, mRNA therapies and more. The ability to synthesize complex sequences is also essential for AI-enabled drug discovery where researchers need their AI-generated sequences manufactured exactly, without adding a step to alter the sequences for manufacturability. By delivering genes with novel and complex structures combined with a transparent online ordering and tracking process, Twist enables customers to advance cutting edge research, empowering the development of new and next-generation therapeutics.